Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Casimersen (Primary) ; Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 01 Nov 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 11 Oct 2019 Planned End Date changed from 30 Jun 2026 to 10 Aug 2026.
- 11 Oct 2019 Planned primary completion date changed from 30 Jun 2026 to 10 Aug 2026.